Compare COSM & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COSM | OSRH |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 18.4M |
| IPO Year | 2009 | N/A |
| Metric | COSM | OSRH |
|---|---|---|
| Price | $0.36 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 594.0K | 387.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,426,402.00 | N/A |
| Revenue This Year | $20.69 | N/A |
| Revenue Next Year | $53.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $0.28 | $0.38 |
| 52 Week High | $1.32 | $4.33 |
| Indicator | COSM | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 46.42 |
| Support Level | $0.35 | $0.39 |
| Resistance Level | $0.50 | $0.74 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.33 | 43.08 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.